RetinalGenix Technologies Inc.

Equities

RTGN

US76133Y1055

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 17:47:02 22/02/2024 GMT			5-day change	1st Jan Change
3.5 ^USD	+12.90%		-.--%	+13.27%

05-20	RetinalGenix Technologies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-01	RetinalGenix Technologies Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

RetinalGenix Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

August 19, 2022 at 09:26 pm

RetinalGenix Technologies Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was USD 0.359335 million compared to USD 0.534852 million a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.01 a year ago.
For the six months, net loss was USD 0.734534 million compared to USD 1.22 million a year ago. Basic loss per share from continuing operations was USD 0.05 compared to USD 0.03 a year ago.

Latest news about RetinalGenix Technologies Inc.

RetinalGenix Technologies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-20	CI
RetinalGenix Technologies Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
RetinalGenix Technologies Inc. announced that it has received $4.65 million in funding	02-08	CI
RetinalGenix Technologies Inc. announced that it expects to receive $4.65 million in funding	01-22	CI
RetinalGeniX?? Technologies Inc. Contracts with Medsan, Inc. to Provide Diagnostic Testing Services for Its Institutional Review Board to Conduct a Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular Degeneration	12-26	CI
RetinalGeniX Technologies Inc. Appoints Anatoly Dritschilo, M.D. to the Medical Advisory Board	12-21	CI
RetinalGeniX Technologies Inc. Appoints Dessislava Boneva to its Board of Directors	12-04	CI
RetinalGenix Technologies Inc. Appoints Virender Ahluwalia as Interim Chief Financial Officer	12-01	CI
RetinalGenix Technologies Inc. Appoints Stephen Tannenbaum to the Business Advisory Board	11-28	CI
RetinalGenix Technologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
RetinalGeniX Technologies Inc. Announces the Submission of Two Provisional Patent Applications for Investigational Therapeutic Drugs	11-09	CI
RetinalGeniX Contracts With Avania CRO to Provide Guidance for Interactions With FDA on Development of Two Drug Therapies and the RetinalCam? Image Visualization Device	11-08	CI
RetinalGeniX Technologies Inc. Announces Institutional Review Board Approves to Conduct Study to Personalize Medical Evaluations for Patients Receiving Treatment for Wet Macular Degeneration	30/10/23	CI
RetinalGenix Technologies Inc. Appoints Fred Chasalow to the Medical Advisory Board of DNA-GPS	28/08/23	CI
RetinalGenix Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
RetinalGenix Technologies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	18/05/23	CI
RetinalGenix Technologies Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	31/03/23	CI
RetinalGenix Technologies Inc. Auditor Raises 'Going Concern' Doubt	30/03/23	CI
RetinalGenix Technologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	17/11/22	CI
RetinalGenix Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	19/08/22	CI
RetinalGenix Technologies Inc. Appoints Vinay Mehindru to its Board of Directors	26/07/22	CI
RetinalGenix Technologies Inc. acquired DNA/GPS Inc. from Lawrence Perich for $14 million.	05/07/22	CI
RetinalGenix Technologies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	13/05/22	CI
RetinalGenix Technologies Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	15/04/22	CI
RetinalGenix Technologies Inc. Auditor Raises 'Going Concern' Doubt	14/04/22	CI

Chart RetinalGenix Technologies Inc.

Duration

Period

More charts

Company Profile

RetinalGenix Technologies Inc. is an ophthalmic research and development company. The Company is focused on creating solutions to screen, monitor, diagnose, and treat ophthalmic, optical, and sight-threatening disorders and to enable the early detection and treatment of multiple systemic diseases through a combination of therapeutic medications and medical device technologies. The Company is focused on preventing vision loss and blindness due to ocular diseases, including diabetic retinopathy and maculopathy, in its first two devices: Retinal Imaging Screening Device and RetinalCam. Retinal Imaging Screening Device is a portable, retinal imaging system providing a wide field of view without requiring pupil dilation. RetinalCam is an in-home/remote location patient-activated monitoring and imaging device offering real time communication and alerting system for physicians available 24/7. The Company is also engaged in the development of its product candidates: RTG-2023 and RTG-2024.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
RETINALGENIX TECHNOLOGIES INC.	+13.27%	62.25M
MODERNA, INC.	+43.36%	54.63B
IQVIA HOLDINGS INC.	-5.31%	39.92B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-11.83%	10.74B

Other Biotechnology & Medical Research